HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTNATIONAL PHASE 1 / 2 TRIAL OF HG004 FOR INHERITED BLINDNESS

HuidaGene Therapeutics New Jersey China

HG004 is the first China-developed AAV gene therapy medicine to be evaluated in a multinational, master-protocol clinical trial for patients with inherited retinal dystrophies caused by mutations in RPE65 geneHG004 is also first China independently-developed gene therapy drug granted both ODD and RPDD by the U.S. FDAHG004 is Company's first product candidate from robust pipeline of ophthalmology and neurology advances into the clinicor visit http://clinicaltrials.gov

About HuidaGene - ????
HuidaGene Therapeutics (????) is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing novel gene-editing tools and gene therapies to rewrite the future of genomic medicine. Based in Shanghai and New Jersey, HuidaGene is committed to addressing patients' needs globally with various preclinical therapeutic programs covering ophthalmology and neurology. We are currently advancing clinical programs of HG004 in inherited retinal disease caused by RPE65 mutations (which has been granted both ODD and RPDD by U.S. FDA), HG202 CRISPR/Cas13Y RNA-editing in neovascular age-related macular degeneration (nAMD), and our preclinical pipeline, including programs HG301 CRISPR/Cas12 DNA-editing in retinitis pigmentosa, HG204 CRISPR/Cas13Y RNA-editing in neurodevelopmental disease of MECP2 duplication syndrome (MDS) (which has been granted RPDD and ODD by U.S. FDA), and HG302 CRISPR/Cas12 DNA-editing in neuromuscular diseases of Duchenne muscular dystrophy (DMD) etc. Company's CRISPR-based therapeutics offer the potential to cure patients with life-threatening conditions by repairing the cause of their disease. HuidaGene is committed to transforming the future of genome-editing medicine.

For more information, please visit http://www.huidagene.com
or follow us on LinkedIn at http://www.linkedin.com/company/huidagene

Logo - https://mma.prnewswire.com/media/1990114/Huidagene_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/huidagene-therapeutics-announces-first-patient-dosed-in-multnational-phase-12-trial-of-hg004-for-inherited-blindness-301972650.html

Anzeige

Rätst du noch bei deiner Aktienauswahl oder investierst du schon nach einem profitablen System?

Ein Depot ohne klare Strategie ist im aktuellen Börsenumfeld ein unkalkulierbares Risiko. Überlass deine finanzielle Zukunft nicht länger dem Zufall oder einem vagen Bauchgefühl. Der Börsenbrief 'trading-notes' nimmt dir die komplexe Analysearbeit ab und liefert dir konkrete, überprüfte Top-Chancen. Mach Schluss mit dem Rätselraten und melde dich jetzt für 100% kostenloses Expertenwissen an.
Jetzt abonnieren .